title: [Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif® Tablets)].
authors.forename: Makoto
authors.initials: M
authors.lastname: Tahara
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shibata
authors.forename: Shinya
authors.initials: S
authors.lastname: Katsura
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004791:Enzyme Inhibitors; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D051379:Mice; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000187:drug effects; D009368:Neoplasm Transplantation; D009570:Nitriles / Q000494:pharmacology* / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009570:Nitriles; D011804:Quinolines; D013607:Tablets; C471992:bosutinib; D016044:Fusion Proteins, bcr-abl